The Lattice Study is a multi-centre clinical trial evaluating the safety and effectiveness of an oral investigational drug to see if it may reduce symptoms of moderate-to-severe Crohn’s disease.
The study involves patients aged 18 to 75 years who have been diagnosed with moderate-to-severe Crohn’s disease for 3 months or more, who have tried at least one Crohn’s disease medication that did not work or stopped working.
The primary outcome measure of the study will be patients achieving remission of their Crohn’s disease, assessed by either a clinical activity score or inspection of the bowel with an endoscope, within 12 weeks.
